The Genomics and Biomarker Program, The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
J Oncol. 2012;2012:709049. doi: 10.1155/2012/709049. Epub 2012 Dec 23.
Despite the widespread use of conventional and contemporary methods to detect ovarian cancer development, ovarian cancer remains a common and commonly fatal gynecological malignancy. The identification and validation of early detection biomarkers highly specific to ovarian cancer, which would permit development of minimally invasive screening methods for detecting early onset of the disease, are urgently needed. Current practices for early detection of ovarian cancer include transvaginal ultrasonography, biomarker analysis, or a combination of both. In this paper we review recent research on novel and robust biomarkers for early detection of ovarian cancer and provide specific details on their contributions to tumorigenesis. Promising biomarkers for early detection of ovarian cancer include KLK6/7, GSTT1, PRSS8, FOLR1, ALDH1, and miRNAs.
尽管常规和现代方法已被广泛用于检测卵巢癌的发展,但卵巢癌仍然是一种常见且通常致命的妇科恶性肿瘤。目前迫切需要鉴定和验证高度特异于卵巢癌的早期检测生物标志物,从而开发出用于检测疾病早期发生的微创筛查方法。目前卵巢癌的早期检测方法包括经阴道超声、生物标志物分析或两者的结合。本文综述了用于早期检测卵巢癌的新型和稳健生物标志物的最新研究,并详细介绍了它们在肿瘤发生中的作用。用于早期检测卵巢癌的有前途的生物标志物包括 KLK6/7、GSTT1、PRSS8、FOLR1、ALDH1 和 miRNAs。